You can now read 5 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

Jazz Pharmaceuticals

Continue reading below

The maker of the narcolepsy medicine Xyrem rose on its deal to buy EUSA Pharma Inc. for $650 million to diversify its drug holdings, including a therapy for leukemia. Acquiring closely held EUSA, based in Langhorne, Pa., will immediately add to earnings, Dublin-based Jazz said, and increase 2013 revenue by $210 million to $230 million. EUSA posted first-quarter net sales of $46 million.

Loading comments...
Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
Please enter a valid email will never post anything without asking.
Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of